GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ASKA Pharmaceutical Holdings Co Ltd (TSE:4886) » Definitions » Cash Flow from Financing

ASKA Pharmaceutical Holdings Co (TSE:4886) Cash Flow from Financing : 円0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is ASKA Pharmaceutical Holdings Co Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, ASKA Pharmaceutical Holdings Co paid 円0 Mil more to buy back shares than it received from issuing new shares. It received 円0 Mil from issuing more debt. It paid 円0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received 円0 Mil from paying cash dividends to shareholders. It received 円0 Mil on other financial activities. In all, ASKA Pharmaceutical Holdings Co spent 円0 Mil on financial activities for the three months ended in Dec. 2023.


ASKA Pharmaceutical Holdings Co Cash Flow from Financing Historical Data

The historical data trend for ASKA Pharmaceutical Holdings Co's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ASKA Pharmaceutical Holdings Co Cash Flow from Financing Chart

ASKA Pharmaceutical Holdings Co Annual Data
Trend Mar22 Mar23 Mar24
Cash Flow from Financing
-2,996.00 -1,820.00 -3,943.00

ASKA Pharmaceutical Holdings Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ASKA Pharmaceutical Holdings Co Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

ASKA Pharmaceutical Holdings Co's Cash from Financing for the fiscal year that ended in Mar. 2024 is calculated as:

ASKA Pharmaceutical Holdings Co's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ASKA Pharmaceutical Holdings Co  (TSE:4886) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

ASKA Pharmaceutical Holdings Co's issuance of stock for the three months ended in Dec. 2023 was 円0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

ASKA Pharmaceutical Holdings Co's repurchase of stock for the three months ended in Dec. 2023 was 円0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

ASKA Pharmaceutical Holdings Co's net issuance of debt for the three months ended in Dec. 2023 was 円0 Mil. ASKA Pharmaceutical Holdings Co received 円0 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

ASKA Pharmaceutical Holdings Co's net issuance of preferred for the three months ended in Dec. 2023 was 円0 Mil. ASKA Pharmaceutical Holdings Co paid 円0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

ASKA Pharmaceutical Holdings Co's cash flow for dividends for the three months ended in Dec. 2023 was 円0 Mil. ASKA Pharmaceutical Holdings Co received 円0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

ASKA Pharmaceutical Holdings Co's other financing for the three months ended in Dec. 2023 was 円0 Mil. ASKA Pharmaceutical Holdings Co received 円0 Mil on other financial activities.


ASKA Pharmaceutical Holdings Co Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of ASKA Pharmaceutical Holdings Co's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


ASKA Pharmaceutical Holdings Co (TSE:4886) Business Description

Traded in Other Exchanges
N/A
Address
2-5-1 Shibaura, Minato-ku, Tokyo, JPN, 108-8532
ASKA Pharmaceutical Holdings Co Ltd is engaged in the manufacturing, sale, import, export, clinical examinations and testing operations of pharmaceuticals, quasi-drugs, foods, veterinary drugs, feeds and feed additives and medical devices and related operations.

ASKA Pharmaceutical Holdings Co (TSE:4886) Headlines

No Headlines